NCT06640738View on ClinicalTrials.gov

Investigating the Optimal Remifentanil and Dexmedetomidine Concentration for Uterine Fibroid Ablation

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Uterine Fibroids (UF)
Interventions
DRUG

arm 2

"This study tries to find the best drug concentration of Remifentanil, ALVOGEN® (2 mg/vial) in Uterine Fibroid Ablation. We have two arms. Arm 1 with Remifentanil, ALVOGEN® (2 mg/vial) 1.0 ng/mL, and arm 2 with Remifentanil, ALVOGEN® (2 mg/vial) 2.0 ng/mL, both given via a syringe infusion pump, Perfusor® Space \

DRUG

arm 1

"This study tries to find the best drug concentration of Remifentanil, ALVOGEN® (2 mg/vial) in Uterine Fibroid Ablation. We have two arms. Arm 1 with Remifentanil, ALVOGEN® (2 mg/vial) 1.0 ng/mL, and arm 2 with Remifentanil, ALVOGEN® (2 mg/vial) 2.0 ng/mL, both given via a syringe infusion pump, Perfusor® Space \

All Listed Sponsors
lead

Kaohsiung Medical University

OTHER

NCT06640738 - Investigating the Optimal Remifentanil and Dexmedetomidine Concentration for Uterine Fibroid Ablation | Biotech Hunter | Biotech Hunter